Myeloproliferative Neoplasms Panel - blood or bone marrow only.


Sunquest Code:NGSONCoPath Code:NGSO
Epic Code:LAB6497Epic Name:Next Generation Sequencing Oncology
Synonyms:Complete Myeloproliferative Panel; Complete Myeloproliferative Neoplasm Panel; Short Myeloproliferative Panel; Short Myeloproliferative Neoplasm Panel; MPL, CALR, JAK2, BCR
Methodology:Next generation sequencing and real-time PCR BCR-ABL1, MPN
CPT Code:----------CPTCODES HERE----------
Test Includes:Short myeloproliferative neoplasm panel includes next generation sequencing of JAK2, CALR and MPL genes. The complete panel I includes next generation sequencing of JAK2, CALR and MPL genes and real-time PCR of BCR-ABL1 major (p210) quantitative and/or minor (p190) quantitative.
Turnaround Time:Performed Mon-Fri; results are reported within 10-14 days.
Special Instructions:Refer to requisition form for available tests. (See Associated Links). For non-EPIC sites: Print out requisition(s) and check gene(s) or panel requested. Order testing in EPIC as Complete or Short Myeloproliferative Panel.
Associated Links:

MDL Oncology Tumor Marker Request Form, NGSON Order Instructions



Collection Instructions

Specimen:Blood or bone marrow
Optimal Volume:10 mL blood; 3 mL bone marrow
Minimum\Peds Volume:3 mL blood; 1 mL bone marrow
Container:Yellow (ACD, Solution A) tube available from laboratory (Purple (EDTA))
Collection Instructions:Follow the NGSON Order Instructions prior to sample collection. See Associated Links.
Causes for Rejection:Frozen or clotted specimen, incorrect anticoagulant, specimen more than 5 days old.
Shared blood and bone marrow samples will not be accepted unless sent to Molecular first. Contamination will occur on automated hematology analyzers. Samples for BCRABL testing must arrive within 72 horus of collection or testing will be cancelled.


Processing and Shipping

Specimen Processing:Whole blood. Do not process. Store at room temperature.
Shipping Instructions:Ship at room temperature. Do not refrigerate or freeze.
Test Performed at or Referral Lab Molecular Diagnostics  (UMMC-East Bank)


Interpretive

Reference Range:See interpretive report.
Use:This multi-gene panel is alternatively ordered in suspicious myeloproliferative neoplasma (MPN) for patients who require results for all three genes to result at the same day without delay. The 2017 WHO diagnostic criteria includes molecular testing for JAK2, CALR, and MPL mutations for MF and ET and molecular testing for JAK2 V617F or JAK2 exon 12 mutations for PV. JAK2 mutations (exon 14 or 12) are present in approximately all polycythemia vera (PV) patients; however, JAK2 mutations are present in only 60-65% of both essential thrmbocythemia (ET) and primary myelofibrosis (MF) patients. CALR mutations are present in 20-25% of both ET and MF; while MPL mutations are associated with improved survival compared to JAK2 mutations and "triple-negative" myelofibrosis; and CALR mutations are associated with lower risk of thrombosis compared to JAK2 mutations. The "triple-negative" mutation status (lack of all 3 "driver" mutations - JAK2, CALR or MPL) occurs in approximtely 10% of MF patients and is associated with worse prognosis.


Click HERE to Report test errors or omissions.
*If no email program is associated with this computer, please contact:
systemlabguide@fairview.org for TestID: 6323"